Biosimilar cancer drug CDP1 aims to match cetuximab in advanced tumors
NCT ID NCT03491709
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests a new drug called CDP1, which is a biosimilar (a close copy) of the approved cancer drug cetuximab. The trial enrolls adults with advanced colorectal cancer or head and neck squamous cell carcinoma that has not responded to prior treatments. Researchers compare how the body processes CDP1 versus cetuximab and check for side effects. The goal is to see if CDP1 is a safe and similar alternative to cetuximab.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CDP1 (anti-EGFR monoclonal antibody, similar to cetuximab)
- What this could lead to
- If CDP1 works as well as cetuximab, it could offer a more affordable treatment option for advanced colorectal and head and neck cancers.
- What could go wrong
- This is a small, early-phase study focused on safety and drug levels, not yet on effectiveness. The drug may not prove as effective or safe as cetuximab in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai East Hospital Phase 1 Clinical Trial Center
Shanghai, Shanghai Municipality, 201203, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we predict who will survive a bowel surgery leak?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- A mobile app aims to turn health awareness into action — a trial puts it to the test
- Can a walking routine alter cancer biomarkers? new trial investigates
- Web tool aims to empower rare cancer patients in genomic choices